Acrivon Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Acrivon Therapeutics (ACRV).

Price Target Range — 10 Quarters

Analyst Consensus — 9 Analysts

2S.Buy

6Buy

1Hold

Consensus RatingMarket Outperform# Analysts9Avg. Consensus PT$18Upside to Avg. PT+920.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jan 9, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$6→$8
Nov 25, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$19
Aug 14, 2025	Oppenheimer	Matthew Biegler	PT Cut	Outperform	$9→$8
May 16, 2025	Jones Trading	Soumit Roy	Downgrade	Buy→Hold	—
May 15, 2025	Oppenheimer	Matthew Biegler	PT Cut	Outperform	$10→$9
Mar 28, 2025	Oppenheimer	Matthew Biegler	PT Cut	Outperform	$18→$10
Mar 28, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$19
Mar 26, 2025	Cantor Fitzgerald	Li Watsek	Maintained	Overweight	—
Mar 26, 2025	Citizens Capital Markets	Silvan Tuerkcan	Maintained	Market Outperform	$17
Mar 26, 2025	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$22→$19
Jan 31, 2025	Cantor Fitzgerald	Li Watsek	Initiate	Overweight	—
Nov 14, 2024	BMO Capital	Etzer Darout	PT Cut	Outperform	$28→$27
Nov 14, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$22
Sep 16, 2024	JMP Securities	Silvan Tuerkcan	Maintained	Market Outperform	$17
Sep 16, 2024	Ladenburg Thalmann	Aydin Huseynov	Upgrade	Neutral→Buy	$16
Sep 16, 2024	BMO Capital	Etzer Darout	PT Raise	Outperform	$25→$28
Sep 16, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$22
Aug 13, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$22
May 15, 2024	BMO Capital	Etzer Darout	Maintained	Outperform	$25
May 14, 2024	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$20→$22

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $8

Piper Sandler analyst Edward Tenthoff maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price target from $6 to $8.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $19 price target.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $8

Oppenheimer analyst Matthew Biegler maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and lowers the price target from $9 to $8.

Benzinga Newsdesk

PRO
Jones Trading Downgrades Acrivon Therapeutics to Hold

Jones Trading analyst Soumit Roy downgrades Acrivon Therapeutics (NASDAQ:ACRV) from Buy to Hold.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $19 price target.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Acrivon Therapeuticsto Overweight

Cantor Fitzgerald analyst Li Watsek reiterates Acrivon Therapeutics (NASDAQ:ACRV) from Overweight to Overweight.

Benzinga Newsdesk

Acrivon Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Acrivon Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $8

PRO
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target

PRO
Oppenheimer Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $8

PRO
Jones Trading Downgrades Acrivon Therapeutics to Hold

PRO
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on Acrivon Therapeuticsto Overweight

People Also Watch

People Also Watch

Acrivon Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Acrivon Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $8

PROHC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target

PROOppenheimer Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $8

PROJones Trading Downgrades Acrivon Therapeutics to Hold

PROHC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target

PROCantor Fitzgerald Reiterates Overweight on Acrivon Therapeuticsto Overweight

People Also Watch

People Also Watch

PRO
Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $8

PRO
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target

PRO
Oppenheimer Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $8

PRO
Jones Trading Downgrades Acrivon Therapeutics to Hold

PRO
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on Acrivon Therapeuticsto Overweight